Forbes features LexaGene: Next big breakthrough
This Forbes full-length feature on LexaGene and our technology describes how LexaGene could be the next big medical breakthrough. > Read now.
Coronavirus news recap
LexaGene CEO and Founder Dr. Jack Regan explains the threat of the current coronavirus outbreak and recaps LexaGene’s latest news describing the company’s role in preventing the spread of pathogens like coronavirus.
Cleanroom Technology article
Shortcomings in traditional culture testing leave the cannabis industry in search of methods that can enumerate or count the presence of microbes whether dead or alive. LexaGene CEO Dr. Jack Regan presents an alternative in the Cleanroom Technology article on LexaGene’s DNA-driven pathogen detection for cannabis-hemp products.
LexaGene introduced in Forbes
LexaGene was mentioned in this Forbes article as a solution provider tackling the challenge of improving food safety and reducing recalls.
Digital Journal Antibiotic Resistance Q&A
Digital Journal sits down with LexaGene CEO Dr. Regan to discuss the challenge of antibiotic resistance threats and how LexaGene’s LX Analyzer can help improve antibiotic stewardship.
LexaGene in Cleanroom Technology
LexaGene’s beta installation at CDX cannabis testing facilities featured in Cleanroom Technology. The article describes how LexaGene is bringing better detection to the cannabis testing market.
Boston Business Journal article
Boston Business Journal featured LexaGene in a story about how the company is trying to tackle possible under-reporting of EEE virus.
LexaGene featured on CBS Boston 4
LexaGene was featured on CBS Boston 4 WBZ during the news reporting of the EEE virus outbreak in Massachusetts
and other states.
Feature on Investing News Network
Read Investing News Network’s story on LexaGene – LexaGene Tackling Antibiotic Resistance with Genetic Analyzer.
Interview on EEE Testing
LexaGene CEO Dr. Jack Regan speaks to Proactive Investors explaining what LexaGene is doing to help respond to the rising threat of EEE Virus in Massachusetts and other states. Watch video.
LexaGene discusses ASL beta testing for Human Clinical
LexaGene CEO Dr. Jack Regan discusses beta testing client Assurance Scientific Laboratories (ASL) and their plans to use the LX Analyzer prototype in human clinical diagnostics. Watch video.
BioSpace article on LexaGene antibiotic resistance testing
Read BioSpace article on LexaGene’s news: The CDC and FDA AR Isolate Bank will provide information to LexaGene which will support the company’s diagnostics development and help address the serious issue of antibiotic resistance.